The Pfizer and Moderna COVID-19 vaccines appear to be safe for people with inflammatory bowel diseases (IBD), a new study finds. are chronic conditions caused b

Rheumatoid arthritis (RA) is associated with restrictive and obstructive spirometry patterns, with the strongest associations seen for severe patterns, accordin

No cases of postdural puncture headache (PDPH) were reported in a cohort of patients receiving spinal injections with smaller or larger needles for spinal anest

People with irritable bowel syndrome (IBS) had milder symptoms during the COVID-19 lockdown, possibly due to reduced stress levels and more control over their d

Do you know What causes gastritis? Get complete details about common Signs and symptoms of gastritis with all reasons behind it.

Taking nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen doesn t make COVID-19 worse or more deadly, a new study finds. When the pandemic began, d

Older women with low levels of vitamin D may have more pain after total knee replacement than those with adequate levels of the nutrient, a new study suggests.

SUNDAY, Dec. 20, 2020 Chronic pain can be excruciating, debilitating and hard to describe. Yet the best way to get the right treatment for the exact pain you re

Electroacupuncture treatment was linked to statistically and clinically significant reductions in back-pain specific disability.

It happens more often than you might think, so don’t fear—but do follow up.

If you plan to have hip replacement surgery, you’ll want a highly qualified orthopedic surgeon to perform the procedure. Hive 80 member Amy, shares Healthgrades article on how to find the best orthope

Kelly Young had rheumatoid arthritis symptoms for years, but her doctors didn’t take them seriously or thought she was making them up.

“I became a hermit. I stayed in and stopped socializing. I wasn’t ‘me’ any longer.”

Growing up, 60-year-old Janet Scott had dreams of being a dancer. She was a regular at the local theatre, where she would longingly watch the performers dancing with their “lovely long legs”. But when she turned 16, Scott started to realise that her legs weren’t like the dancers - or in fact, like any

Medtronic plc (MDT) has announced statistically significant 12-month results from a large, multicenter trial (RCT) that it says further proves the superiority of DTM Spinal Cord Stimulation (SCS) in back pain relief, vs conventional SCS therapy, using the Medtronic Intellis platform.At 12 months, 84% of patients with chronic back pain treated with DTM SCS reported at least 50% pain relief, compared to 51% of patients treated with conventional SCS.There was also a difference in the proportion of patients who reported profound back pain relief favoring DTM SCS (69%) compared with conventional SCS (35.1%).The study met its primary endpoint at three months, and in pre-specified secondary analysis showed the superiority of DTM SCS compared to conventional SCS and has sustained these results at 12 months.Pain relief was measured by the Visual Analog Scale (VAS), a widely used measure for pain intensity that records pain levels on a scale of 0-10. Fifty-percent pain relief is a recognized industry standard to define therapy success. The majority of DTM SCS patients in this study exceeded this threshold, with seven out of ten experiencing profound back pain relief at 12 months.Patients treated with DTM SCS also reported an average VAS score reduction of 75% in back pain, compared with 50% treated with conventional SCS. Average VAS scores for patients treated with DTM SCS at 12 months were 1.74 for back pain and 1.45 for leg pain.“More than two-thirds of the patients in this RCT achieved profound pain relief of at least 80% with DTM SCS therapy,” said Michael Fishman of the Center for Interventional Pain & Spine. ” These outcomes demonstrate that DTM SCS can provide more patients profound pain relief compared with conventional SCS at 12 months, which physicians should consider when selecting a neuromodulation therapy for their patients.”Shares in MDT are down 4% year-to-date, but the stock scores a bullish Strong Buy consensus from the Street. That’s with a $120 average analyst price target indicating 10% upside potential lies ahead.“Between delays in the development of its robotic system or the stumbles in Diabetes, MDT will still need to prove that it can be a consistent 5% grower, but with MDT’s markets growing at 5% roughly, M&A should provide a cushion to the top-line” comments BTIG analyst Ryan Zimmerman.He reiterated his buy rating on MDT with a $119 price target arguing that: “Investors should not expect incrementally more return to the bottom line as the focus will be top-line growth reinvestment, but in a market where top-line growth is highly rewarded, we think this strategy makes sense.” (See MDT stock analysis on TipRanks).Related News: Simmons’ 3Q EPS Beats Estimates; Analyst Sticks To Buy Crown Holdings Posts 3Q Profit Win, Initiates Dividend Pay Zions Beats 3Q Profit; Street Says Hold More recent articles from Smarter Analyst: * BD’s Covid-19-Flu Combo Test Wins European Clearance * KeyCorp’s Profit Rises As Credit Loss Provisions Drop 20% * Telia Inks 5G Network Deals With Ericsson, Nokia * Prologis' 2020 Outlook Tops Estimates; Street Says Buy

Patients with chronic pain and depression have benefited from a mindfulness-based stress reduction course.

/PRNewswire/ -- Weekend warriors, physically active people and others needing pain relief have a new option to help relieve joint and muscle pain. Vizuri...

Back pain is the second most common reason for missing work behind catching a cold. In Part II of this series of five-minute strength workouts, Stephanie Mansour shares how to help stabilize the lumbar spine and engage the abdominals to bring relief.